Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, single arm, open phase IV clinical trial to evaluate the efficacy and safety of co-administration of Abilify [aripiprazole] with Depakote [divalproate; valproate semisodium] in the 6-week treatment of acute mania in patients with bipolar disorder.

Next Previous
X
Search
Trial Profile

Multi-center, single arm, open phase IV clinical trial to evaluate the efficacy and safety of co-administration of Abilify [aripiprazole] with Depakote [divalproate; valproate semisodium] in the 6-week treatment of acute mania in patients with bipolar disorder.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary) ; Valproate semisodium
  • Indications Bipolar disorders
  • Focus Therapeutic Use
  • Acronyms SMART-A
  • Sponsors Korea Otsuka Pharmaceutical

    • Most Recent Events

    • 24 Jun 2010 Actual end date (June 2010) added as reported by ClinicalTrials.gov.
    • 24 Jun 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Planned end date (Dec 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top